Clinical Trial Update: BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

BeOne Medicines is conducting a Phase 1 trial evaluating BGB-21447, a Bcl-2 inhibitor, in combination regimens for adults with hormone receptor-positive, HER2-n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• BGB-21447 (BGB-21447)

Snippet

Sponsor: BeOne Medicines | Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Status: RECRUITING